*ST Shuangcheng Receives GMP Compliance Inspection Approval

Deep News08-26

On August 26, Hainan Shuangcheng Pharmaceuticals Co.,Ltd. (002693) announced that it recently received a "Drug GMP Compliance Inspection Notice" approved and issued by the Hainan Provincial Drug Administration. The inspection was conducted from June 11 to 13, 2025, covering workshops and production lines for freeze-dried powder injections and raw materials (somatostatin). The inspection conclusion showed that the company complies with Good Manufacturing Practice requirements for pharmaceutical production.

The successful completion of this GMP compliance inspection demonstrates that the company's production quality management system for the relevant workshops and production lines meets industry standards, helping the company maintain stable production capacity to meet market demand. However, the announcement also noted that due to the special nature of the pharmaceutical industry, drug production and sales are subject to various factors including market environment, industry policies, and supply-demand relationships, which create certain uncertainties.

In the first half of 2025, Hainan Shuangcheng Pharmaceuticals achieved revenue of 84.12 million yuan and a net loss attributable to shareholders of 18.47 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109128585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109128585","market":"us","top_or_hot":-1,"title":"*ST Shuangcheng Receives GMP Compliance Inspection Approval","media":"Deep News","content":"<p>On August 26, Hainan Shuangcheng Pharmaceuticals Co.,Ltd. (002693) announced that it recently received a \"Drug GMP Compliance Inspection Notice\" approved and issued by the Hainan Provincial Drug Administration. The inspection was conducted from June 11 to 13, 2025, covering workshops and production lines for freeze-dried powder injections and raw materials (somatostatin). The inspection conclusion showed that the company complies with Good Manufacturing Practice requirements for pharmaceutical production.</p>\n<p>The successful completion of this GMP compliance inspection demonstrates that the company's production quality management system for the relevant workshops and production lines meets industry standards, helping the company maintain stable production capacity to meet market demand. However, the announcement also noted that due to the special nature of the pharmaceutical industry, drug production and sales are subject to various factors including market environment, industry policies, and supply-demand relationships, which create certain uncertainties.</p>\n<p>In the first half of 2025, Hainan Shuangcheng Pharmaceuticals achieved revenue of 84.12 million yuan and a net loss attributable to shareholders of 18.47 million yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>*ST Shuangcheng Receives GMP Compliance Inspection Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n*ST Shuangcheng Receives GMP Compliance Inspection Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-08-26 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On August 26, Hainan Shuangcheng Pharmaceuticals Co.,Ltd. (002693) announced that it recently received a \"Drug GMP Compliance Inspection Notice\" approved and issued by the Hainan Provincial Drug Administration. The inspection was conducted from June 11 to 13, 2025, covering workshops and production lines for freeze-dried powder injections and raw materials (somatostatin). The inspection conclusion showed that the company complies with Good Manufacturing Practice requirements for pharmaceutical production.</p>\n<p>The successful completion of this GMP compliance inspection demonstrates that the company's production quality management system for the relevant workshops and production lines meets industry standards, helping the company maintain stable production capacity to meet market demand. However, the announcement also noted that due to the special nature of the pharmaceutical industry, drug production and sales are subject to various factors including market environment, industry policies, and supply-demand relationships, which create certain uncertainties.</p>\n<p>In the first half of 2025, Hainan Shuangcheng Pharmaceuticals achieved revenue of 84.12 million yuan and a net loss attributable to shareholders of 18.47 million yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002693","symbol_name":"*ST双成","start_time":0,"source_url":"","article_id":"1109128585","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109128585","pubTimestamp":1756209017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"On August 26, Hainan Shuangcheng Pharmaceuticals Co.,Ltd. (002693) announced that it recently received a \"Drug GMP Compliance Inspection Notice\" approved and issued by the Hainan Provincial Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002693":"*ST双成","BK0239":"医药制造"},"translate_title":"*ST双城获GMP符合性检查批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002693":1},"content_text":"On August 26, Hainan Shuangcheng Pharmaceuticals Co.,Ltd. (002693) announced that it recently received a \"Drug GMP Compliance Inspection Notice\" approved and issued by the Hainan Provincial Drug Administration. The inspection was conducted from June 11 to 13, 2025, covering workshops and production lines for freeze-dried powder injections and raw materials (somatostatin). The inspection conclusion showed that the company complies with Good Manufacturing Practice requirements for pharmaceutical production.\nThe successful completion of this GMP compliance inspection demonstrates that the company's production quality management system for the relevant workshops and production lines meets industry standards, helping the company maintain stable production capacity to meet market demand. However, the announcement also noted that due to the special nature of the pharmaceutical industry, drug production and sales are subject to various factors including market environment, industry policies, and supply-demand relationships, which create certain uncertainties.\nIn the first half of 2025, Hainan Shuangcheng Pharmaceuticals achieved revenue of 84.12 million yuan and a net loss attributable to shareholders of 18.47 million yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109128585","isCrawlerRequest":true}